Menu
Boston, MA and Lausanne, Switzerland, November 17th, 2020: SOPHiA GENETICS, leader in Data-Driven Medicine, announced today that Bram Goorden joined its Executive team, holding the dual role of Chief Commercial Officer and Head of North America. Goorden comes to SOPHiA from Foundation Medicine Inc. (Cambridge, MA) where he held the role of VP of International Business and Partnering, in charge of expanding the company’s global footprint.
“Bram is an amazing addition to our leadership team as he is well-versed in building top performing teams and developing lasting commercial relationships with healthcare stakeholders that are of immense benefit to all involved. He will be a great driver of our US and Global expansion plans moving forward as he champions the future of Data-Driven Medicine in both the Clinical and BioPharma Business Units,” affirmed founder and CEO Jurgi Camblong.
Bram Goorden, a Belgian national, is an accomplished commercial executive with 20 years of experience in life sciences. Before FMI, he was General Manager, Head of Therapeutics with Prometheus Labs (San Diego, CA), a Nestle Health Science company. Earlier in his career, Goorden held global revenue driving roles of increasing responsibility with Eli Lilly and UCB Pharma. He originally began his career as a management consultant at Accenture where he worked with clients in biotech, utilities and petrochemicals.
“I am thrilled to join the SOPHiA team. Our universal Platform is democratizing Data-Driven Medicine in an unparalleled fashion. Together, we enable healthcare providers to fully utilize the power of decentralized genomic and multimodal data in their efforts to improve patient outcomes. It’s a privilege to help grow access to our solution for both clinicians and biopharma partners in my role as Chief Commercial Officer,” said Bram Goorden.
Goorden is now based from the company’s US headquarters in Boston. As part of the closing of a recent successful $110 Million oversubscribed funding round, SOPHiA GENETICS has plans to nearly triple their workforce in the United States.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
